## Ø 003/006 Ø 002/003

FEB 0 9 2007

RECEIVED

PTO/SE/82 (01-06)
Approved for use through 12/31/2008, OMB 0651-0038
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperweik Reduction Act of 1995, por persons are required to mappend to a collection of information unless if displays a yair OMB central number.

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND

CHANGE OF CORRESPONDENCE ADDRESS

pond to a collection of information un	HIGO; U.S. DEPARTMENT OF COMMERCI Insa if (lisplaya a yalid OMD control number
Application Number	10/801,118
Filing Date	March 15, 2004
First Named Inventor	Jul H. Wang
Art Unit	1633
Examiner Name	Janet L. Epps Ford
Attorney Docket Number	DNPP-02007US0

I hereby revoke all previou	is powers of attorney give	on in the above-ide	ntified appli	cation	
☐ A Power of Attorney is			1111100	Cauon,	
OR					
I hereby appoint the pr	ractitioners associated with	the Customer Numb	er:	66936	
Please change the corre	espondence address for the	above-identified ap	plication to:		
The address assoc Customer Number	tated with	56936			
OR		WAL			
Firm or Individual Name					****
Address	- Variance	The state of the s			
City	W	State		Zip	
Country		***************************************			·····
Telephone		Emall			
I am the:  Applicant/Inventor.		<u> </u>			
Assignee of record of Statement under 37 Ci	the entire interest. See 37 ( FR 3.73(b) is enclosed. (For	DFR 3,71, rm PTO/SB/96)		·	
Si-natura	SIGNATURE of Applican	it or Assignee of Re	ecord	·	
Signature Neurcy A	lide				
F3_1_	NP Pharmaceuticals, Inc.	·		•••	<del></del>
Date for 30, 2	007	Telephone (	416) 995-2480		•
NOTE: Signatures of all the inventors or as signature is required, see below.	signess of moord of the amire interest	or their representative(s) are	required, Submit r	multiple forms # more than o	ne
*Total of 2forms are	submitted.				

This collection of information is required by 37 CFR 1.30. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the senount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Pasent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES DR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-8004PTO-9199 and select option 2.

## RECEIVED CENTRAL FAX CENTER

Ø 004/006 Ø 003/003

FEB **0 9** 2007

PTO/SE/06 (09-00) U.S. Pelent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number STATEMENT UNDER 37 CFR 3,73(b) Applicant/Patent Owner: DNP Pharmocoulicals, Inc. Application No./Patent No.: 10/801,118 Filed/Issue Date: March 15, 2004 Entitled: POLY-DNP-SIRNA DNP Phormoceuticals, Inc Composition (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.) 1. The assignee of the entire right, title, and interest; or 2. An assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is In the patent application/patent identified above by virtue of either: A An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 015022 \_\_\_ Frame\_0489\_\_\_ \_\_\_\_, or for which a copy B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignce as follows: The document was recorded in the United States Patent and Trademark Office at Rect \_, Frame or for which a copy thereof is attached. 2. From: To: The document was recorded in the United States Patent and Trademark Office at . Frame or for which a copy thereof is attached. 3. From: The document was recorded in the United States Patent and Trademark Office at Recl \_, Frame \_ ,, or for which a copy thereof is attached. Additional documents in the chain of title are listed on a supplemental sheet. As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.081 The undersigned (whose title is supplied below) is authorized to act on behall of the assignoe. Signature Nancy Dudneon for DNP Pharmaceuticals, Inc. (418) 995-2480 Printed or Typed Name Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to fite (and by the USPTO to process) en application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, inducing gathering, preparing, and submitting the conjusted application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Palent and Trademark Office, U.S. Department of Communes, P.O. Box 1450, Alexandria, VA 22313-1450.

FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

It you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

President and Chief Executive Officer